SANA-01 ADC
SANA-01 ADC.
Built to bind better.
Built to battle more cancers.
SANA-01 ADC
A novel MUC-1 antibody that’s engineered for unmatched specificity and wide therapeutic index.
Our Epitope Discovery Platform revealed a more stable, first-in-class MUC-1 epitope in cancers. And it’s already redefining what’s possible for therapeutic antibody development for solid tumors.
A novel MUC-1 antibody that’s engineered for unmatched specificity and wide therapeutic index.
Our Epitope Discovery Platform revealed a more stable, first-in-class MUC-1 epitope in cancers. And it’s already redefining what’s possible for therapeutic antibody development for solid tumors.
More contact points. More possibilities.
By binding to a longer, more stable epitope, SANA-01 antibody makes more contacts with an affinity and specificity rarely seen in drug development, creating a precision hand-in-glove fit.
More contact points. More possibilities.
By binding to a longer, more stable epitope, SANA-01 antibody makes more contacts with an affinity and specificity rarely seen in drug development, creating a precision hand-in-glove fit.
Lower doses. Fewer side effects.
Higher affinity and specificity don’t just create new possibilities. They can reduce dosage and potential side effects, helping patients fight cancer faster and more comfortably.
Lower doses. Fewer side effects.
Higher affinity and specificity don’t just create new possibilities. They can reduce dosage and potential side effects, helping patients fight cancer faster and more comfortably.
Better outcomes for more patients.
SANA-01 antibody is designed to help more patients in a broader range of cancers than other MUC-1 antibodies in development today.
Better outcomes for more patients.
SANA-01 antibody is designed to help more patients in a broader range of cancers than other MUC-1 antibodies in development today.